|
|
Post by mindovermatter on Nov 22, 2015 13:40:14 GMT -5
Torrey Pines and MannKind already have a partnership. Yes. Strange that some frequent posters see this as news and post it as if this is a big new thing. A bit like Teva and now Pfizer (because they have an address in Connecticut: what?). What is missing from this pain partnership is $ to actually move this partnership forward. Maybe someone will make a commection with a Swiss company because there are banks in Switzerland and there is money in those banks. Onvious right? It does seem that there is a group of online posters that enjoy connecting dots that frankly don't connect. And if i recall, Torrey Pines is/was having financial difficulties too and that put the pain trials it had hoped to start in 2014 on ice. |
|
|
|
Post by mindovermatter on Nov 22, 2015 12:59:05 GMT -5
via laborer75 @stocktwits ( I wonder if s/he's on this list  ) Inventors on Mannkind Corporation patents (2015) A list of inventors with patent application filings associated with Mannkind Corporation for 2015. Note: Some Mannkind Corporation-related inventors may appear under alternate organization names/spellings. Inventors are listed solely due to being on a related/assigned patent, and may not be affiliated in any way with the organization. Browse by year: 2015 2014 2013 2012 2011 2010 - Mannkind Corporation patents Alexis Mollard Alfred E. Mann Anders Hasager Boss Andras Toro Andrea Leone-bay Benoit Adamo Brendan Laurenzi Carl R. Sahi Chad C. Smutney Chih-sheng Chiang Cohava Gelber Dennis Overfield Donald Costello Gary A. Flynn George R. MartinBrowse by year: 2015 2014 2013 2012 2011 2010 - Mannkind Corporation patents (click highlighted link at top for years previous to 2015).... Wow, didn't know George R Martin was also a scientist! He did predict winter was coming for Afrezza.  |
|
|
|
Post by mindovermatter on Nov 20, 2015 12:31:19 GMT -5
I'll take any bet that Al Mann makes AF eat his words. AF is a small small man. Many of us shareholders have been waiting many years for this. Hasn't happened now and don't think it ever will. But what I don't understand is why so many have such hate for the guy. He's not the one who has put Mannkind in the position they are now. He only reports on it with his twist of dislike for the company. |
|
|
|
Post by mindovermatter on Nov 20, 2015 11:17:54 GMT -5
I just got to work, opened my computer and looked at MNKD - wow - a shocker! (I don't look anymore from home, the morning commute is stressful enough) I'm surprised more don't think this may have come at least in part from Sanofi, not saying it did, but it's a possibility. If it happens to be true, that's great news, because it tells me SNY cares (about its significant investment in Afrezza). Good luck to Hakan, I'm sure he tried his best and put in many long hours over the years. Sometimes, you just need a change. The choice of successor will go a long way in telling us just how that SNY-MNKD relationship is going. Sadly, we'll never know the real reason. It's just too bad that they weren't able to have someone lined up to buffer the news of his departure. Looks like I might have to ask the wife for permission to take more than one shot of Glenlivet tonight. |
|
|
|
Post by mindovermatter on Nov 20, 2015 10:50:54 GMT -5
Wherever Hakan goes, I hope he takes Matt with him. We need to clear the decks and start fresh with a a top flight CEO and CFO. Trend Matt has been the voice of the company now for months. He is the one out front, arranging for the TASE deal. He is the one that everyone who emails the company goes to....and he answers! He has been the only one on the conference calls to portray any confidence and "hope". But, we don't need Matt to be promoted. We need someone to come in and take over who has a great track record with a positive reputation that WS can back. It would have been nice if the BOD had found a replacement before Haakan went. But clearly, he was fired. If it was mutual and both sides agreed, there would have been a replacement. Even if he was desperately ill and couldn't continue one more day, others would have covered for him while they found a new CEO. Nope...this was the Board finally taking action. I hope not too late! And there lies the problem. How many companies have their CFO also double as the company spokesman and censor of their CEO. Matt has had to hush up not just Al but Hakan as well. The company is in a serious tail spin and one can only wonder if it can get out of it before it crashes and burns. |
|
|
|
Post by mindovermatter on Nov 20, 2015 9:48:57 GMT -5
in general I view this action as necessary and overdue. My immediate concern is that the same Board of Directors who just removed Hakan also promoted him several months ago. It has been discussed on the board as though the decision was Al's; but in the end, the BOD has to take responsibility. Al controls the BOD, imo. They do what he wants.
Another question is how will SNY view this? Perhaps their lack of a definitive endorsement two weeks ago had something to do with their reservations about current executive management.
Maybe this all stemmed from Sanofi?
Maybe they didn't like Hakan?JMHO Chris C |
|
|
|
Post by mindovermatter on Nov 20, 2015 9:45:23 GMT -5
Finally Hakan aloof "man with a mission" Edstrom is gone. Last conference call was pathetic and his comments asking for help were the writing on the wall. This is very positive news; possibly the best all year. Script count today was better than the last few weeks. I see today's management shakeup as an excellent move from a deadweight CEO who was confusing and hard to understand with a major lack of enthusiasm. Wasn't it Al who hand picked him to succeed him as CEO? |
|
|
|
Post by mindovermatter on Nov 20, 2015 9:27:34 GMT -5
I see it positive as Al taking over the interim position. If his health wasn't good likely the BOD would not have given the reins back to him until they find a new CEO, Assuming they are looking for one. We don't know what is going on and under the circumstances, there might have been no other choice but for Al to take over. |
|
|
|
Post by mindovermatter on Nov 20, 2015 9:20:02 GMT -5
I'd say go contact Martin Shkreli. He, at least, would remove any doubt that Mannkind is finished if he came on and saying that Afrezza and Technoshpere were the future of drug delivery. |
|
|
|
Post by mindovermatter on Nov 20, 2015 8:32:31 GMT -5
Wow! Another hit for the company and another story for the shorts to have a field day with. I wonder if Hakan is not well because this seemed rather sudden.
|
|
|
|
Post by mindovermatter on Nov 18, 2015 14:47:21 GMT -5
Unfortunately, the black whole surrounding everything Mannkind gives posters like Rrtz, if not credibility, yes a soap box from where to keep spreading FUD. In any case, whether a short, a paid baser, or just some sort of MB lurking organism without much else to do his agenda is pretty clear. I keep reading about FUD and those who post not so flattering posts about Mannkind. What determines what is FUD vs what is a real and genuine criticism of the company? Is the "FUD" from message boards the reason why Wall Street is so negative on the company and why Afrezza isn't selling like many of us thought it would? Help me understand why there is such a concern for those who post unflattering things about Mannkind because in the grand picture, it's just white noise and has nothing to do with why the stock has been a popular pinata for Wall Street to smack around. |
|
|
|
Post by mindovermatter on Nov 18, 2015 12:43:48 GMT -5
Oh yay, some upage. Low volume uppy. Regardless, it is good to see some green. My favorite color is green, It's a joy when it shows on my screen. Now you can take red and put it to bed I won't miss it if it's never seen.
too early in the trading day. We have seen how quickly this can be taken down. Green is good only when the market closes at 4PM. |
|
|
|
Post by mindovermatter on Nov 17, 2015 19:48:26 GMT -5
Maybe I missed it but why would Sanofi want to keep EU launch a secret? It didn't keep US launch a secret. What exactly would they gain by "surprising" anyone and everyone by doing so?
|
|
|
|
Post by mindovermatter on Nov 16, 2015 14:27:46 GMT -5
Debt financing is pretty much off the table now. They were barely able to refinance a small amount of converts a few months ago. The Al Mann line of credit is off-market terms. Mnkd needs to stand on its own two feet. In other words, relying on non-market financing from a shareholder is really not a sustainable way forward. Really, their only option is equity. However, raising hundreds of millions is going to be difficult. Not sure anyone would underwrite such a huge offering as I suspect demand is not strong given the deteriorating business outlook. Maybe they could get it done with a big discount to market, although I doubt it. Even so, I suspect shareholders would not be satisfied with the pricing terms. Most concerning would be the message it would send about near term expectations of script growth and afrezza profits (or lack thereof). No offense, but this financing strategy is not very well thought out. Agree it is not easy for Mannkind to raise funds right now after we have missed so many good opportunities in the last several quarters. See what Exact Sciences Corporation has recently done with their capital raises. Jul 21, 2015 Previous Release | Next Release PDF Add to Briefcase Exact Sciences Announces Pricing of Public Offering of Common Stock MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (NASDAQ: EXAS) today announced that Jefferies LLC and Robert W. Baird & Co. Incorporated, the underwriters of the Company's previously announced public offering of 7,000,000 shares of common stock, are reoffering the shares to the public at an initial price of $25.50 per share. The Company has also granted the underwriters an option to purchase up to 1,050,000 of additional shares. The offering is expected to close on or about July 24, 2015, subject to customary closing conditions. Dec 16, 2014 Previous Release | Next Release PDF Add to Briefcase Exact Sciences Announces Pricing of Public Offering of Common Stock MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (NASDAQ: EXAS) today announced the pricing of the public o ffering of 4,000,000 common shares previously sold to Jefferies LLC and Robert W. Baird & Co. Incorporated, as underwriters of the offering. The common shares will be sold at a public offering price of $25.75 per share. The Company has also granted the underwriters an option to purchase up to 600,000 additional shares. The offering is expected to close on or about December 19, 2014, subject to customary closing conditions. 11 million shares at $25.50/25.75. Now they are also in a tough position to raise funds due to not so great ramp up of Cologuard. But they took advantage of the good opportunities to raise $280 million plus funds. So they can wait for another good time to raise funds within the next two years with $343 million in their bank account. Tough or unpopular as it may be, Mannkind needs to do something to take the bankruptcy talks/rumors off the table. It never has been easy for Mannkind to raise money and why Al was the one to fund it to the tune of almost a billion of his own dollars and most likely will need to pony up again. Unless Afrezza breaks out and Mannkind starts to show nice profits, the company will not be able to raise money on Wall Street. It's also why it went the TASE route but that, most likely, was a one shot deal too. |
|
|
|
Post by mindovermatter on Nov 16, 2015 12:45:04 GMT -5
Compound, Your post was among the best I've ever seen on this board. I hope you follow through with the suggestion to forward your post to Matt and Hakan. Trend I actually sent an email to Matt last night, outline the points raised in my original post. I have not heard anything back yet. I think you guys may also consider writing to Matt (mpfeffer@mannkindcorp.com) to emphasize the importance of put our financing in order. If I was running Mannkind, I would not ever let its cash balance to dip below $100 million. Under a normal circumstance, I would like to keep it at around $300 million level and ideally at $500 million level. But now what we got from the management. I am still a strong believer in Afrezza and I do not mind Mannkind spending another five years to slowly make it a blockbuster. But, to do that, they have to first ensure that they can survive for another five years and show that to the world. If they can do that, Mannkind will be a winner. I applaud you for writing to CFO, but what do you think he'll be able to tell you that will change anything? He legally can not get into details of what is going on and you already know that. The company is in an awkward position right now. The best thing it can do is show it can move its technosphere program forward with a new drug candidate and partner. But does anyone think that is going to happen by the end of the year? I don't. |
|
)
